TriangleNCT00396331 · OUTCOME
Median Number of Days to Platelet (PLT) Engraftment
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Days
- Interval / dispersion
- Full Range
- Time frame
- Approximately 2 months (1 month post transplant)
What was measured
The number of days from transplantation to successful engraftment as measured by platelet value of \>=20\*10\^9/L for 7 days without transfusion.
Analysis population: Participants who received a transplant and had a successful PLT engraftment. Seven participants (4 with HD, 2 with MM, and 1 with testicular cancer) received a second transplant. Four transplants (2 in participants with NHL and 2 in participants with MM) did not result in PLT engraftment and are therefore not included in the analysis.
Groups in this outcome
Non-Hodgkin's Lymphoma
Participants with non-Hodgkin's lymphoma (NHL) were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\*10\^6 CD34+ cells/kg were collected.
Hodgkin's Disease
Participants with Hodgkin's disease (HD) were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\*10\^6 CD34+ cells/kg were collected.
Multiple Myeloma
Participants with multiple myeloma (MM) were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\*10\^6 CD34+ cells/kg were collected.
Other Cancers
Participants with 'other' cancers (desmoplastic small round cell tumor, acute myeloid leukemia, and testicular cancer) were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\*10\^6 CD34+ cells/kg were collected.
All Patients
Not reported
| Group | Source count |
|---|---|
| Non-Hodgkin's Lymphoma | 59 |
| Hodgkin's Disease | 16 |
| Multiple Myeloma | 7 |
| Other Cancers | 1 |
| All Patients | 83 |
| Group | Source count |
|---|---|
| Non-Hodgkin's Lymphoma | 59 |
| Hodgkin's Disease | 20 |
| Multiple Myeloma | 9 |
| Other Cancers | 2 |
| All Patients | 90 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Non-Hodgkin's Lymphoma | 21.0 | Not reported | 7.0 | 88.0 | Not reported |
| Hodgkin's Disease | 21.0 | Not reported | 15.0 | 81.0 | Not reported |
| Multiple Myeloma | 19.0 | Not reported | 16.0 | 24.0 | Not reported |
| Other Cancers | 26.0 | Not reported | 3.0 | 49.0 | Not reported |
| All Patients | 21.0 | Not reported | 3.0 | 88.0 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 7.0
- upper Limit
- 88.0
- value
- 21.0
- group Id
- OG001
- lower Limit
- 15.0
- upper Limit
- 81.0
- value
- 21.0
- group Id
- OG002
- lower Limit
- 16.0
- upper Limit
- 24.0
- value
- 19.0
- group Id
- OG003
- lower Limit
- 3.0
- upper Limit
- 49.0
- value
- 26.0
- group Id
- OG004
- lower Limit
- 3.0
- upper Limit
- 88.0
- value
- 21.0
- denom Units Selected
- Participants
- denoms
- counts
- group Id
- OG000
- value
- 59
- group Id
- OG001
- value
- 16
- group Id
- OG002
- value
- 7
- group Id
- OG003
- value
- 1
- group Id
- OG004
- value
- 83
- units
- Participants
- counts
- group Id
- OG000
- value
- 59
- group Id
- OG001
- value
- 20
- group Id
- OG002
- value
- 9
- group Id
- OG003
- value
- 2
- group Id
- OG004
- value
- 90
- units
- Transplants with PLT engraftment
- description
- The number of days from transplantation to successful engraftment as measured by platelet value of \>=20\*10\^9/L for 7 days without transfusion.
- dispersion Type
- Full Range
- groups
- description
- Participants with non-Hodgkin's lymphoma (NHL) were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\*10\^6 CD34+ cells/kg were collected.
- id
- OG000
- title
- Non-Hodgkin's Lymphoma
- description
- Participants with Hodgkin's disease (HD) were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\*10\^6 CD34+ cells/kg were collected.
- id
- OG001
- title
- Hodgkin's Disease
- description
- Participants with multiple myeloma (MM) were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\*10\^6 CD34+ cells/kg were collected.
- id
- OG002
- title
- Multiple Myeloma
- description
- Participants with 'other' cancers (desmoplastic small round cell tumor, acute myeloid leukemia, and testicular cancer) were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\*10\^6 CD34+ cells/kg were collected.
- id
- OG003
- title
- Other Cancers
- id
- OG004
- title
- All Patients
- param Type
- MEDIAN
- population Description
- Participants who received a transplant and had a successful PLT engraftment. Seven participants (4 with HD, 2 with MM, and 1 with testicular cancer) received a second transplant. Four transplants (2 in participants with NHL and 2 in participants with MM) did not result in PLT engraftment and are therefore not included in the analysis.
- reporting Status
- POSTED
- time Frame
- Approximately 2 months (1 month post transplant)
- title
- Median Number of Days to Platelet (PLT) Engraftment
- type
- SECONDARY
- type Units Analyzed
- Transplants with PLT engraftment
- unit Of Measure
- Days
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice